Filter Results:
(792)
Show Results For
- All HBS Web
(1,551)
- People (1)
- News (333)
- Research (792)
- Multimedia (8)
- Faculty Publications (573)
Show Results For
- All HBS Web
(1,551)
- People (1)
- News (333)
- Research (792)
- Multimedia (8)
- Faculty Publications (573)
Sort by
- October 2020 (Revised November 2023)
- Case
COVID-19 Testing at Everlywell
By: Jeffrey J. Bussgang and Olivia Hull
In March 2020, as COVID-19 spreads rapidly across the U.S., Everlywell founder Julia Cheek considers how to respond as a small start-up specializing in at-home lab testing. After making dramatic budget cuts, she decides to pivot the organization to address the... View Details
Keywords: Entrepreneurship; Business Strategy; Venture Capital; Health Care and Treatment; Health Disorders; Leading Change; Technology Adoption; Digital Platforms; Competitive Strategy; Science; Adaptation; Corporate Social Responsibility and Impact; Crisis Management; Social Entrepreneurship; Ethics; Government Legislation; Health; Health Testing and Trials; Health Pandemics; Health Industry; Health Industry; Health Industry; Texas; United States
Bussgang, Jeffrey J., and Olivia Hull. "COVID-19 Testing at Everlywell." Harvard Business School Case 821-001, October 2020. (Revised November 2023.)
- January 1991 (Revised March 1991)
- Case
Prepare/21 at Beth Israel Hospital (A)
In response to escalating cost pressures throughout the hospital industry, the management of Beth Israel Hospital (BI) decided to implement a productivity plan to cut their operating costs. They chose the Scanlon Plan, an employee participation and incentive program... View Details
Keywords: Nonprofit Organizations; Cost Management; Employees; Health Care and Treatment; Health Industry
Friedman, Raymond A. "Prepare/21 at Beth Israel Hospital (A)." Harvard Business School Case 491-045, January 1991. (Revised March 1991.)
- summer 1985
- Article
High-tech Cardiology-Issues and Costs: A Panel Discussion
By: Lynn Sharp Paine and George L. Atkins
Paine, Lynn Sharp, and George L. Atkins. "High-tech Cardiology-Issues and Costs: A Panel Discussion." Pharos of Alpha Omega Alpha Honor Medical Society 48, no. 3 (summer 1985): 31–37.
- February 2008 (Revised August 2012)
- Background Note
Note on Medical Travel
By: Regina E. Herzlinger and Sara Green
Background notes for MedVal and Fortis case studies. View Details
Keywords: Cost; Health Care and Treatment; Cross-Cultural and Cross-Border Issues; Health Industry; Health Industry; India
Herzlinger, Regina E., and Sara Green. "Note on Medical Travel." Harvard Business School Background Note 308-084, February 2008. (Revised August 2012.)
- August 14, 2008
- Article
How Rehospitalizations Are Hurting Medicare
By: Robert C. Pozen
Pozen, Robert C. "How Rehospitalizations Are Hurting Medicare." Boston Globe (August 14, 2008).
- January–February 1994
- Article
Financial Engineering at Merck
By: Timothy A. Luehrman
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
- 01 Jun 2020
- Working Paper Summaries
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
- 2019
- White Paper
Impact-Weighted Financial Accounts: The Missing Piece for an Impact Economy
By: George Serafeim, T. Robert Zochowski and Jennifer Downing
Reimagining capitalism is an imperative. We need to create a more inclusive and sustainable form of capitalism that works for every person and the planet. Massive environmental damage, growing income and wealth disparity, stress, and depression within developed... View Details
Keywords: Impact-Weighted Accounts; IWAI; Background; Economic Systems; Economy; Corporate Social Responsibility and Impact; Measurement and Metrics; Financial Statements
Serafeim, George, T. Robert Zochowski, and Jennifer Downing. "Impact-Weighted Financial Accounts: The Missing Piece for an Impact Economy." White Paper, Harvard Business School, Boston, MA, September 2019.
- June 2015
- Teaching Note
Schӧn Klinik: Measuring Cost and Value
By: Robert S. Kaplan
Teaching Note for Schon Klinik: Measuring Cost and Value. View Details
- 2020
- Working Paper
Revenue Collapses and the Consumption of Small Business Owners in the Early Stages of the COVID-19 Pandemic
By: Olivia S. Kim, Jonathan A. Parker and Antoinette Schoar
Using detailed transaction-level data from financial accounts, this paper shows that the revenues of small businesses and the consumption spending of their owners both decline by roughly 40% following the declaration of the national emergency in March 2020. However,... View Details
Kim, Olivia S., Jonathan A. Parker, and Antoinette Schoar. "Revenue Collapses and the Consumption of Small Business Owners in the Early Stages of the COVID-19 Pandemic." NBER Working Paper Series, No. 28151, November 2022.
- January 1983 (Revised February 1988)
- Case
Hospital Corp. of America (A)
By: W. Carl Kester
HCAs ratio of debt to total capital is approaching 70%, jeopardizing its single-A bond rating. Students must determine an appropriate target debt ratio for HCA in light of its growth objectives, its acquisition strategy and its changing regulatory environment. View Details
Keywords: Situation or Environment; Capital Structure; Health Care and Treatment; Borrowing and Debt; Health Industry; Tennessee
Kester, W. Carl. "Hospital Corp. of America (A)." Harvard Business School Case 283-053, January 1983. (Revised February 1988.)
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- 26 Jul 2016
- First Look
July 26, 2016
confirm that homophily, which here likely arises from social influence, permeates all scales of human behavior. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51392 May 2016 Seminars in Oncology Nursing Transformation of View Details
Keywords: Sean Silverthorne
- July 2021 (Revised July 2022)
- Case
Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care
By: Robert S. Kaplan, Navraj S. Nagra and Syed S. Shehab
Dr. Andrea Pusic, breast cancer reconstruction surgeon, wants to extend outcomes measurement beyond traditional surgical metrics of infections, complications, and survival rates. The case describes her development of a new mobile phone app, which collects patients’... View Details
Keywords: Health Care and Treatment; Outcome or Result; Cost Management; Activity Based Costing and Management; Mobile and Wireless Technology; Health Testing and Trials; Surveys; Health Industry; Boston
Kaplan, Robert S., Navraj S. Nagra, and Syed S. Shehab. "Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care." Harvard Business School Case 122-010, July 2021. (Revised July 2022.)
- September 2016
- Article
Value Based Care and Bundled Payments: Anesthesia Care Costs for Outpatient Oncology Surgery Using Time-driven Activity-based Costing
By: Katy E. French, Alexis B. Guzman, Augustin C. Rubio, John C. Frenzel and Thomas Feeley
Background:
With the movement towards bundled payments, stakeholders should know the true cost of the care they deliver. Time-driven activity-based costing (TDABC) can be used to estimate costs for each episode of care. In this analysis, TDABC is used to both... View Details
French, Katy E., Alexis B. Guzman, Augustin C. Rubio, John C. Frenzel, and Thomas Feeley. "Value Based Care and Bundled Payments: Anesthesia Care Costs for Outpatient Oncology Surgery Using Time-driven Activity-based Costing." Healthcare: The Journal of Delivery Science and Innovation 4, no. 3 (September 2016): 173–180.
- August 1999
- Teaching Note
Dana-Farber Cancer Institute: Development Strategy, The (TN)
Teaching Note for (9-599-104). View Details
- September 2022
- Article
Cost of Cardiac Stereotactic Body Radioablation Therapy versus Catheter Ablation for Treatment of Ventricular Tachycardia
By: Chen Wei, Michelle Boeck, Pierre C. Qian, Todd Vivenzio, Zoe Elizee, Jeremy S. Bredfeldt, Robert S. Kaplan, Usha Tedrow, Raymond Mak and Paul C. Zei
Cardiac SBRT is a novel way of treating refractory ventricular tachycardia (VT) that may be less costly than catheter ablation, owing to its noninvasive, outpatient nature. We applied time-driven activity-based costing to both procedures. The direct and total... View Details
Wei, Chen, Michelle Boeck, Pierre C. Qian, Todd Vivenzio, Zoe Elizee, Jeremy S. Bredfeldt, Robert S. Kaplan, Usha Tedrow, Raymond Mak, and Paul C. Zei. "Cost of Cardiac Stereotactic Body Radioablation Therapy versus Catheter Ablation for Treatment of Ventricular Tachycardia." Pacing and Clinical Electrophysiology 45, no. 9 (September 2022): 1005–1179.
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- December 2005 (Revised April 2010)
- Teaching Note
Leerink Swann & Co.: Creating Competitive Advantage (TN)
By: Boris Groysberg and Andrew N. McLean